ECSP22080858A - Variantes de anticuerpos felinos - Google Patents

Variantes de anticuerpos felinos

Info

Publication number
ECSP22080858A
ECSP22080858A ECSENADI202280858A ECDI202280858A ECSP22080858A EC SP22080858 A ECSP22080858 A EC SP22080858A EC SENADI202280858 A ECSENADI202280858 A EC SENADI202280858A EC DI202280858 A ECDI202280858 A EC DI202280858A EC SP22080858 A ECSP22080858 A EC SP22080858A
Authority
EC
Ecuador
Prior art keywords
antibodies variants
feline antibodies
feline
variants
feline antibody
Prior art date
Application number
ECSENADI202280858A
Other languages
English (en)
Inventor
Luis CAMPOS Henry
Marie Bergeron Lisa
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of ECSP22080858A publication Critical patent/ECSP22080858A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

La invención se refiere generalmente a variantes de anticuerpos felinos y usos de estos. Específicamente, la invención se refiere a mutaciones en la región constante del anticuerpo felino para mejorar su semivida y otras características.
ECSENADI202280858A 2020-04-17 2022-10-17 Variantes de anticuerpos felinos ECSP22080858A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063011491P 2020-04-17 2020-04-17

Publications (1)

Publication Number Publication Date
ECSP22080858A true ECSP22080858A (es) 2023-01-31

Family

ID=75870744

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202280858A ECSP22080858A (es) 2020-04-17 2022-10-17 Variantes de anticuerpos felinos

Country Status (16)

Country Link
US (1) US20240067730A1 (es)
EP (1) EP4136109A1 (es)
JP (1) JP2023522030A (es)
KR (1) KR20230005158A (es)
CN (1) CN115667300A (es)
AU (1) AU2021257355A1 (es)
BR (1) BR112022020631A2 (es)
CA (1) CA3176434A1 (es)
CL (1) CL2022002856A1 (es)
CO (1) CO2022014684A2 (es)
EC (1) ECSP22080858A (es)
IL (1) IL297290A (es)
MX (1) MX2022012793A (es)
PE (1) PE20230348A1 (es)
TW (1) TW202204404A (es)
WO (1) WO2021212084A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021012513A2 (pt) 2019-01-03 2021-09-14 Invetx Inc. Composições para aumentar a meia-vida de um agente terapêutico em caninos e métodos de uso
EP4149969A1 (en) 2020-05-11 2023-03-22 Invetx, Inc. Compositions for increasing half-life of a therapeutic agent in canines and methods of use
WO2022010652A1 (en) 2020-07-10 2022-01-13 Invetx Inc. Compositions for increasing half-life of a therapeutic agent in felines and methods of use
WO2022072446A1 (en) * 2020-09-29 2022-04-07 Zoetis Services Llc Feline antibody variants

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5698762A (en) 1994-12-09 1997-12-16 Dauerman; Leonard Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons
US20030031671A1 (en) 2001-08-01 2003-02-13 Sydney Welt Methods of treating colon cancer utilizing tumor-specific antibodies
KR20070057839A (ko) 2004-08-19 2007-06-07 제넨테크, 인크. 변경된 이펙터 기능을 갖는 폴리펩티드 변이체
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
DK1817340T3 (da) 2004-11-12 2012-08-13 Xencor Inc Fc-varianter med ændret binding til fcrn
RS63063B1 (sr) 2010-08-19 2022-04-29 Zoetis Belgium S A Anti-ngf antitela i njihova upotreba
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
US9617334B2 (en) 2012-06-06 2017-04-11 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof

Also Published As

Publication number Publication date
WO2021212084A1 (en) 2021-10-21
BR112022020631A2 (pt) 2022-11-29
AU2021257355A1 (en) 2022-11-03
CO2022014684A2 (es) 2022-11-08
JP2023522030A (ja) 2023-05-26
MX2022012793A (es) 2022-11-07
US20240067730A1 (en) 2024-02-29
PE20230348A1 (es) 2023-03-02
CA3176434A1 (en) 2021-10-21
TW202204404A (zh) 2022-02-01
CL2022002856A1 (es) 2023-06-02
CN115667300A (zh) 2023-01-31
IL297290A (en) 2022-12-01
KR20230005158A (ko) 2023-01-09
EP4136109A1 (en) 2023-02-22

Similar Documents

Publication Publication Date Title
ECSP22080858A (es) Variantes de anticuerpos felinos
CO2022014695A2 (es) Variantes de anticuerpos caninos
CO2017005650A2 (es) Anticuerpos anti-interleucina-33
EA202092847A1 (ru) Антитела к cd3 и их применение
EA201891582A1 (ru) Иммуностимулирующие гуманизированные моноклональные антитела против интерлейкина-2 человека и их слитые белки
TR201901841T4 (tr) Her antikorlarının sabit dozlaması.
EA202092435A3 (ru) Моноклональные антитела против bcma
CL2023000896A1 (es) Receptores quiméricos de dll3 y métodos para su uso
EA201891040A1 (ru) Конъюгаты антитела, содержащие агонисты толл-подобного рецептора
EA201792467A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
MA40609B1 (fr) Agents de liaison cd123 et leurs utilisations
EA202191763A1 (ru) Бифункциональная молекула анти-pd-1/sirp
ECSP23030271A (es) Variantes de anticuerpos caninos
EA201992776A1 (ru) Белки на основе антитела с привитым цитокином и способы их применения при иммунных нарушениях
CO2023004107A2 (es) Variantes de anticuerpos felinos
EA201991736A1 (ru) Антитело против оболочечного herv-k и его применение
CL2020002459A1 (es) Variantes de anticuerpo c-terminales
CO2023007829A2 (es) Mutaciones en regiones constantes de anticuerpos felinos
CO2023007146A2 (es) Variantes de anticuerpos bovinos
ECSP23057156A (es) Mutaciones en regiones constantes de anticuerpos caninos
EA202192532A1 (ru) Мирикизумаб для применения в способе лечения болезни крона
TR202019577U4 (tr) Abajur bağlanti aparatinda yeni̇li̇k
TR202104726A2 (tr) Köfte form maki̇nasinda yeni̇li̇k
EA202192998A1 (ru) CLEC12a-СВЯЗЫВАЮЩИЕ ПОЛИПЕПТИДЫ И ИХ ПРИМЕНЕНИЕ
EA202192113A1 (ru) Антитела, распознающие тау